Despite recent developments in novel therapeutics including anti-TNF-α antibodies for IBD [12], interest continues to be directed toward probiotics, prebiotics, or fermented medicines as either a treatment modality or maintenance therapy. Here, TNF is linked to inflammatory bowel disease.